Trial Profile
A Randomised, Double-Blind, Vehicle-Controlled Study of the Safety and Tolerability of BTX 1204 in Patients with Mild to Moderate Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Sponsors Botanix Pharmaceuticals
- 04 Sep 2018 Status changed from recruiting to completed.
- 06 Jun 2018 Results presented in the Botanix Pharmaceuticals media release.
- 19 Feb 2018 Planned End Date changed from 31 Jan 2018 to 30 Mar 2018.